Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2004-12-29
2009-06-30
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C544S244000
Reexamination Certificate
active
07553825
ABSTRACT:
Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV,wherein:Y1Aand Y1Bare independently Y1;RX1and RX2are independently RX;Y1is ═O, —O(RX), ═S, —N(RX), —N(O)(RX), —N(ORX), —N(O)(ORX), or —N(N(RX) (RX));RXis independently R1, R2, R4, W3, or a protecting group;R1is independently —H or alkyl of 1 to 18 carbon atoms;R2is independently R3or R4wherein each R4is independently substituted with 0 to 3 R3groups or taken together at a carbon atom, two R2groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R3groups;R3is R3a, R3b, R3cor R3d, provided that when R3is bound to a heteroatom, then R3is R3cor R3d;R3ais —H, —F, —Cl, —Br, —I, —CF3, —CN, N3, —NO2, or —OR4;R3bis ═O, —O(R4), ═S, —N(R4), —N(O)(R4), —N(OR4), —N(O)(OR4), or —N(N(R4) (R4));R3cis —R4, —N(R4)(R4), —SR4, —S(O)R4, —S(O)2R4, —S(O)(OR4), —S(O)2(OR4), —OC(R3b)R4, —OC(R3b)OR4, —OC(R3b)(N(R4)(R4)), —SC(R3b)R4, —SC(R3b)OR4, SC(R3b)(N(R4)(R4)), —N(R4)C(R3b)R4, —N(R4)C(R3b)OR4, N(R4)C(R3b)(N(R4)(R4)), W3or —R5W3;R3dis —C(R3b)R4, —C(R3b)OR4, —C(R3b)W3, —C(R3b)OW3or —C(R3b)(N(R4)(R4));R4is —H, or an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;R5is alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2 to 18 carbon atoms;W3is W4or W5;W4is R6, —C(R3b)R6, —C(R3b)W5, —SOM2R6, or —SOM2W5, wherein R6is R4wherein each R4is substituted with 0 to 3 R3groups;W5is carbocycle or heterocycle wherein W5is independently substituted with 0 to 3 R2groups; andM2 is 0, 1 or 2;and pharmaceutically acceptable salts thereof.
REFERENCES:
patent: 4816570 (1989-03-01), Farquhar
patent: 4968788 (1990-11-01), Farquhar
patent: 5663159 (1997-09-01), Starrett, Jr. et al.
patent: 5792756 (1998-08-01), Starrett, Jr. et al.
patent: 5977061 (1999-11-01), Holy et al.
patent: 6312662 (2001-11-01), Erion et al.
patent: 2002/0119443 (2002-08-01), Becker et al.
patent: 2003/0072814 (2003-04-01), Maibach et al.
patent: 2003/0187261 (2003-10-01), Havlicek et al.
patent: 2003/0219727 (2003-11-01), Becker et al.
patent: 2005/0222090 (2005-10-01), Cheng et al.
patent: 2006/0046981 (2006-03-01), Shibata
patent: WO 91/19721 (1991-12-01), None
patent: WO 01/49688 (2001-07-01), None
patent: WO 2005/066189 (2005-07-01), None
Holy, Collection of Czechoslovak Chemical Communications (2001), 66(10), 1545-1592.
Zidek, et al., European Journal of Pharmacology (2003), 475(1-3), 149-159.
Benzaria et al. “Synthesis, In Vitro Antiviral Evaluation, and Stability Studies of Bis(S-acyl-2-thioethyl) Ester . . . ” 39:4958-4965; J Med Chem., 1996.
Bundgaard et al. “Design and Application of Prodrugs.”p. 113-191; Textbook of Drug Design and Development., 1991.
Christensen et al.“In Vivo anti-papilomavirus Activity of Nucleoside Analogues Including Cidofovir on CRPV-induced Rabbit . . . ” 48:131-142; Antiviral Resjournal., 2000.
De Lombaert et al. “N-Phosphonomethyl Dipeptides and heir Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase . . . ” 37:498-511; J Med Chem., 1994.
Draize et al. “Methods for the Study of Irritation and Toxicity of Substances Applied Topically to the Skin and Mucous Membranes.” 82:377-390; J Pharm Pharmacol., 1944.
Farquhar et al. “Biologically Reversible Phosphate-Protective Groups.”72:324-325; J Pharm Sci., 1983.
Keith et al.“Evalution of Nucleoside Phosphonates and Their Analogs and Prodrugs for Inhibition of Orthopozvirus Replication.” 47(7): 2193-2198; Antimicro AG & Chemo., 2003.
Khamnei et al. “Neighboring Group Catalysis in the Design of Nucleotide Prodrugs.”39:4109-4115; J Med Chem., 1996.
Mitchell et al. “Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4 acyloxybenzyl) and . . . ” 2345;J Chem Soc Perkin Trans I., 1992.
Paquette, Leo A. “Three-Membered Rings with One Hetero Atom.”Chptr:1;Principals of Modern Heterocyclic Chemistry., 1968.
Paquette, Leo A. “The Four-Membered Heterocyles.”Chptr:3;Principals of Modern Heterocyclic Chemistry., 1968.
Paquette, Leo A. “Furan, Pyrrole, and Thiophene.”Chptr:4;Principals of Modern Heterocyclic Chemistry., 1968.
Paquette, Leo A. “The Azoles.”Chptr:6;Principals of Modern Heterocyclic Chemistry., 1968.
Paquette, Leo A. “The Pyridine Group.”Chptr:7;Principals of Modern Heterocyclic Chemistry., 1968.
Paquette, Leo A. “The Diazines and S-Triazine.”Chptr:9;Principals of Modern Heterocyclic Chemistry., 1968.
Puech et al. “Intracellular delivery of nucleoside monophosphates through a reuctase-mediated activation process.” 22:155-174; Antiviral Res., 1993.
Snoeck et al.“Antivaccinia Activities of Acyclic Nucleoside Phosphonate Derivatives in Epithelial Cells and Organotypic Cultures.” 46(11):3356-3361;Antimicro AG & Chemo., 2002.
Stuttgart, Georg Thieme Verlag“An Overview.”p. 1-20; Protecting Groups., 1994.
Stuttgart, Georg Thieme Verlag“Hydroxyl Protecting Groups.”p. 21-94; Protecting Groups., 1994.
Stuttgart, Georg Thieme Verlag “Diol Protecting Groups.”p. 95-117; Protecting Groups., 1994.
Stuttgart, Georg Thieme Verlag “Carboxyl Protecting Groups.”p. 118-154;Protecting Groups., 1994.
Stuttgart, Georg Thieme Verlag “Carbonyl Protecting Groups.”p. 155-184;Protecting Groups., 1994.
Valerianova et al. “Antitumour Activity of N6-Substituted PMEDAP Derivatives Against T-Cell Lymphoma.”21(3):2057-2064;Anticancer Rsrch, Helenic Anticancer Inst., Athens., 2001.
Valerianova et al. “PMEDAP and it's N6-Substituted Derivatives: Genotoxic Effect and . . . ”23(6):4933-4940;Anticancer Rsrch, Helenic Anticancer Inst., Athens.,2003.
Zidek et al. “Immunobiological Activity of N-[2-(phosphonomethoxy)alkyl] Derivatives of N6-Substituted Adenines, and 2,6-diaminopurines.”475:149-159;European Journ of Pharmacol.
Compton, et al. “9-(2-Phosphonylmethoxyethyl)-N6—cyclopropyl-2,6-diaminopurine (cpr-PMEDAP) as a Prodrug of 9-(2-Phosphonylmethoxyethyl)guanine (PMEG)”,Biochemical Pharmacology, (1999) 58:709-714.
Hatse et al. “N6Cyclopropyl-PMEDAP: A Novel Derivative of 9-(2-Phosphonylmethoxyethyl)- 2,6-diaminopurine (PMEDAP) with Distinct Metabolic, Antiproliferative, and Differentiation—Inducing Properties,”Biochemicla Pharmacology, (1999) 58:311-323.
Rose et al. “In Vivo Antitumor Activity of 9-[2-Phosphonylmethpxy)ethyl]-guanine and Related Phosphonate Nucleotide Analogues,”Journal of National Cancer Institute(1990) 82(6):510-512.
Cheng Xiaoqin
Cook Gary P.
Desai Manoj C.
Doerffler Edward
He Gong-Xin
Berch Mark L
Gilead Sciences, Inc.
Zhang Cynthia H.
LandOfFree
Anti-proliferative compounds, compositions, and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-proliferative compounds, compositions, and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-proliferative compounds, compositions, and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4078560